Hillord Pharmaceutical India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 2.20 Cr
- Revenue Growth 99.40%
- Profit Growth 123.26%
- Ebitda 619.16%
- Net Worth 4301.40%
- Total Assets 437.94%
About Hillord Pharmaceutical India
Hillord Pharmaceutical India Private Limited (HPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 October 2013 and has a history of 11 years and three months. Its registered office is in Namakkal, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹2.20 Cr.
Rangasamy Kiruthika, Kandasamy Kumar, and Saravanan Sengottaian serve as directors at the Company.
Company Details
-
Location
Namakkal, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51397TZ2013PTC019933
-
Company No.
019933
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Oct 2013
-
Date of AGM
28 Sep 2018
-
Date of Balance Sheet
31 Mar 2018
-
Listing Status
Unlisted
-
ROC Code
Roc Coimbatore
Industry
Who are the key members and board of directors at Hillord Pharmaceutical India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rangasamy Kiruthika
|
Director | 17-Oct-2013 | Current |
|
Kandasamy Kumar
|
Director | 17-Oct-2013 | Current |
|
Saravanan Sengottaian
|
Director | 17-Oct-2013 | Current |
Financial Performance of Hillord Pharmaceutical India.
Hillord Pharmaceutical India Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 99.4% increase. The company also saw a substantial improvement in profitability, with a 123.26% increase in profit. The company's net worth Soared by an impressive increase of 4301.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hillord Pharmaceutical India?
In 2018, Hillord Pharmaceutical India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.20 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 2.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jun 2017 | Others | ₹2.20 Cr | Open |
How Many Employees Work at Hillord Pharmaceutical India?
Unlock and access historical data on people associated with Hillord Pharmaceutical India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hillord Pharmaceutical India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hillord Pharmaceutical India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
